A common polymorphism in the 5′ UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy
Name
Somers-2015-A common polymorphis.pdf
Size
966.15 KB
Format
Adobe PDF
Checksum (MD5)
add0b6d17bf9703ea01412a1b4d3151f
Author(s)
Somers, Joanna
Wilson, Lindsay A.
Kilday, John-Paul
Horvilleur, Emilie
Cobbold, Laura C.
Kondrashov, Alexander
Grill, Jacques
Grundy, Richard G.
Bushell, Martin
Willis, Anne E.
Date Issued
September 2015
Journal
Genes & Development
Publisher
Cold Spring Harbor Laboratory Press
Citation
Somers, Joanna, Lindsay A. Wilson, John-Paul Kilday, Emilie Horvilleur, Ian G. Cannell, Tuija A.A. Poyry, Laura C. Cobbold, et al. “A Common Polymorphism in the 5′ UTR of ERCC5 Creates an Upstream ORF That Confers Resistance to Platinum-Based Chemotherapy.” Genes Dev. 29, no. 18 (September 3, 2015): 1891–1896.
Version
Final published version
Abstract
We show that a common polymorphic variant in the ERCC5 5′ untranslated region (UTR) generates an upstream ORF (uORF) that affects both the background expression of this protein and its ability to be synthesized following exposure to agents that cause bulky adduct DNA damage. Individuals that harbor uORF1 have a marked resistance to platinum-based agents, illustrated by the significantly reduced progression-free survival of pediatric ependymoma patients treated with such compounds. Importantly, inhibition of DNA-PKcs restores sensitivity to platinum-based compounds by preventing uORF1-dependent ERCC5 expression. Our data support a model in which a heritable 5′ noncoding mRNA element influences individuals’ responses to platinum-based chemotherapy.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1101/gad.261867.115
